# US 2022/0031768 A1 · Methods of treatment of infections using bacteria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031768 A1
- Document ID: US20220031768A1
- Status: Published application
- Kind: A1
- Application number: 17/503,032
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2018-09-27
- Assignees: Decoy Biosystems, Inc.
- Applicants: Decoy Biosystems, Inc.
- Inventors: Michael J. Newman
- Web page: https://patentgrep.com/patent/US20220031768A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 38/212: {IFN-alpha}
- A61K 39/0258: {Escherichia}
- A61K 39/0275: {Salmonella}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/55594: {from bacteria}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non-viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines.

## Claims

### Claim 1

A method of preventing or treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a composition comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells which have been treated in such a way as to result in about 75% to 99% reduction of lipopolysaccharide (LPS)-associated endotoxin activity when measured by the Limulus Amebocyte Lysate (LAL) assay as compared to untreated, wild-type Gram-negative bacterial cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition contains about 0.01 to 100 ng active LPS per kg body weight of the patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition contains about 2 to 200 ng active LPS per 1×108 cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the intact and substantially non-viable Gram-negative bacterial cells have been treated in such a way as to result in about 85% to 98% reduction of LPS-associated endotoxin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the infection is a viral infection.

### Claim 6 (depends on 5)

The method of claim 5, wherein the viral infection is by hepatitis B virus (HBV) or human immunodeficiency virus (HIV).

### Claim 7 (depends on 1)

The method of claim 1, wherein the administration starts within 24 hours following the infection, or within 2 days, 3 days, 4 days, 5 days, 6 days or 7 days following the infection.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administration starts after at least 24 hours following the infection, or after at least 2 days, 3 days, 4 days, 5 days, 6 days or 7 days following the infection.

### Claim 9 (depends on 1)

The method of claim 1, wherein at least 90%, 95% or 100% of the bacterial cells are non-viable.

### Claim 10 (depends on 1)

The method of claim 1, wherein the bacterial cells are Salmonella or Escherichia cells.

### Claim 11

A pharmaceutical dosage form comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells which have been treated in such a way as to result in about 75% to 99% reduction of lipopolysaccharide (LPS)-associated endotoxin activity when measured by the Limulus Amebocyte Lysate (LAL) assay as compared to untreated, wild-type Gram-negative bacterial cells, wherein the total LPS-associated endotoxin activity is equivalent to about 0.7 ng to 7000 ng active LPS.

### Claim 12 (depends on 11)

The pharmaceutical dosage form of claim 11, wherein the total LPS-associated endotoxin activity is equivalent to about 7 ng to 1400 ng active LPS.

### Claim 13 (depends on 11)

The pharmaceutical dosage form of claim 11, further comprising a second therapeutic agent.

### Claim 14 (depends on 13)

The pharmaceutical dosage form of claim 13, wherein the second therapeutic agent is a cyclooxygenase inhibitor, preferably selected from the group consisting of 6MNA, aspirin, carprofen, diclofenac, fenoprofen, flufenamate, flubiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, naproxen, niflumic acid, piroxicam, sulindac sulphide, suprofen, tenidap, tolmetin, tomoxiprol, zomepirac, celexocib, etodolac, meloxicam, nimesulide, diisopropyl fluorophosphate, L745,337, NS398, rofecoxib, SC58125, S-aminosalicylic acid, ampyrone, diflunisal, nabumetone, paracetamol, resveratrol, salicin, salicylaldehyde, sodium salicylate, sulfasalazine, sulindac, tamoxifen, ticlopidine, valeryl salicylate and combinations thereof.

### Claim 15 (depends on 13)

The pharmaceutical dosage form of claim 13, wherein the second therapeutic agent is an agonist of a stimulatory immune checkpoint preferably selected from the group consisting of CD27, CD28, CD40, CD122, CD137, OX40, GITR and ICOS.

### Claim 16 (depends on 13)

The pharmaceutical dosage form of claim 13, wherein the second therapeutic agent is an antagonist of an inhibitory immune checkpoint preferably selected from the group consisting of A2AR, B7-H3, B7-H4, CTLA-4, IDO, KIR, LAGS, PD-1, PD-L1, TIM-3, and VISTA.

### Claim 17 (depends on 13)

The pharmaceutical dosage form of claim 13, wherein the second therapeutic agent is selected from the group consisting of abacavir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balavir, cidofovir, combivir, dolutegravir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, ecoliever, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitor, interferon type III, interferon type II, interferon type I, interferon, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, nitazoxanide, nucleoside analogues, norvir, oseltamivir (Tamiflu®), peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, protease inhibitor, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, sofosbuvir, stavudine, telaprevir, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, zidovudine and combinations thereof.

### Claim 18 (depends on 13)

The pharmaceutical dosage form of claim 13, wherein the second therapeutic agent is interferon alpha or pegylated interferon.

### Claim 19 (depends on 11)

The pharmaceutical dosage form of claim 11, which contains about 2 to 200 ng active LPS per 1×108 cells.

### Claim 20 (depends on 11)

The pharmaceutical dosage form of claim 11, wherein the intact and substantially non-viable Gram-negative bacterial cells have been treated in such a way as to result in about 90% to 98% reduction of LPS-associated endotoxin.
